Navigation Links
febit's miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
Date:3/1/2010

LEXINGTON, Mass. and HEIDELBERG, Germany, March 1 /PRNewswire/ -- febit today announced that an updated version of  the company's Geniom Biochip containing 58 new discovered sequences in addition to all of the Homo sapiens microRNAs (miRNA) from miRBase version 14 (www.mirbase.org) is now available for cancer research. The 58 new miRNA sequences were found by deep sequencing in a miRNA discovery study performed on an Applied Biosystems SOLiD 3 sequencing system. All 58 miRNAs have been validated using the ABI TaqMan miRNA qRT-PCR assay and are now available for further studies using febit's microarray technology for miRNA-profiling.

Several studies investigating the role of miRNAs showed evidence for their influence in cell development processes. Recently, promising biomarkers for the future diagnosis and differentiation of lung cancer and multiple sclerosis have been published in BMC Cancer and PLoS ONE. The results demonstrated that miRNA biomarkers reliably distinguish between affected and healthy individuals by analysing whole blood samples. Each miRNA is part of a meaningful pattern giving information about individual regulatory processes. Therefore each miRNA of the Geniom Biochip, from either miRBase 14 or the SOLiD sequencing-studies, will be of high scientific impact and can be a potential biomarker candidate or therapeutically relevant molecules.

Peer Staehler, febit's CSO, said: "After the recent publication of promising results in biomarker discovery febit now enhanced its pipeline with novel, well validated content. febit plans to  develop miRNA and other disease-related biomarkers which will help to detect diseases at early stages, diagnose the disease progression and monitor the response to treatment. In our studies we used whole blood, which is a well established sample source in the diagnostic practice."

febit's highly flexible microarray production technology keeps pace with the advances in genomic research and the speed of discovery in this exciting industry. febit's Geniom RT Analyzer platform enables febit's customers to conduct large cohort studies due to the very high degree of automation and sophisticated bioinformatics is then able to interpret data to reveal significant regulatory patterns.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's  product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

The key applications are HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing, and hands-off, amplification free microRNA profiling. Both are taking advantage of the advanced microfluidics of the patented Geniom Biochip to offer the highest degree of automation, flexibility and efficiency available.

For more information, please visit www.febit.com.

Contact: febit group, Eva Sterzel, eva.sterzel@febit.com, +49 (0)6221 6510-300

Russo Partners, Martina Schwarzkopf, martina.schwarzkopf@russopartnersllc.com, +1 212 845-4292

SOURCE febit

Back to top

RELATED LINKS
http://www.febit.com

'/>"/>

SOURCE febit
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. febit First to Offer miRBase 11.0 Biochip
2. Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology
3. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
4. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
5. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
6. NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security
7. Particle Sciences Acquires Additional Space for Operations
8. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
9. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
10. DuPont Accelerating Rate of Productivity Through Additional Plant Breeding
11. ViroPharma to Present at Four Additional Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
(Date:1/18/2017)... to a new market research report "In situ Hybridization Market by Technique (FISH, ... Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by MarketsandMarkets, ... 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... Logo ...
(Date:1/18/2017)... , Jan. 18, 2017 Applied BioMath ... modeling to drug research and development, today announced ... President, and CEO of Applied BioMath, will present ... and Modeling (BAGIM) Meeting on Thursday January 19, ... Cambridge , MA.   Dr. Burke,s talk "Quantitative ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
Breaking Biology Technology:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):